The lipid disorder treatment global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Lipid Disorder Treatment Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The lipid disorder treatment market size has grown rapidly in recent years. It will grow from $9.48 billion in 2023 to $10.69 billion in 2024 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increase in adoption of sedentary lifestyle, rise in working population, rise in awareness regarding the disease and treatment, increase in on-the-desk jobs, growth of familial combined hyperlipidemia incidence.
The lipid disorder treatment market size is expected to see rapid growth in the next few years. It will grow to $17.36 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growing cases of obesity and high cholesterol, increase in prevalence of cardiovascular diseases, growing occurrence of high cholesterol causing heart diseases, rise in the demand for safe and efficient treatments, excessive consumption of alcohol and smoking. Major trends in the forecast period include technological advancements in drug development, product innovation, increase in investments in business expansion, technological advancement in the treatment facilities, clinical advancements.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/lipid-disorder-treatment-global-market-report
Scope Of Lipid Disorder Treatment Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Lipid Disorder Treatment Market Overview
Market Drivers –
The growing cases of obesity and high cholesterol are expected to propel the growth of the lipid disorder treatment market going forward. Obesity is a condition characterized by excessive body fat accumulation, while high cholesterol refers to elevated levels of cholesterol in the blood, which pose significant health risks. Obesity and high cholesterol are on the rise due to unhealthy diets, sedentary lifestyles, genetic predispositions, and environmental influences. Lipid disorder treatment plays a pivotal role in controlling obesity and high cholesterol by combining pharmacological interventions with lifestyle modifications, weight management strategies, patient education, and multidisciplinary care. For instance, in May 2022, according to the World Obesity Atlas 2022, published by the World Obesity Federation, a UK-based non-profit organization, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030, and that number will increase to 4 billion people, or 51% of the global population, by 2035. Therefore, the growing cases of obesity and high cholesterol are driving the growth of the lipid disorder treatment market.
Market Trends –
Major companies operating in the lipid disorder treatment market are developing proprotein convertase subtilisin type 9 (PCSK9) inhibitors to address the need for more effective and targeted therapies in managing high cholesterol levels. PCSK9 inhibitors manage lipid disorders by enhancing the removal of LDL cholesterol from the bloodstream, thereby reducing the risk of cardiovascular events in high-risk patients. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval for Praluent (alirocumab) injection from the U.S. Food and Drug Administration (FDA) to address heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. The unique feature of Praluent injection lies in its ability to block the binding of PCSK9 to the LDL receptor, enhancing the quantity of LDL receptors on liver cell surfaces, consequently facilitating the clearance of LDL and reducing LDL-C levels in the bloodstream.
The lipid disorder treatment market covered in this report is segmented –
1) By Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs
2) By Indication: Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Get an inside scoop of the lipid disorder treatment market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15600&type=smp
Regional Insights –
North America was the largest region in the lipid disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited
Table of Contents
1. Executive Summary
2. Lipid Disorder Treatment Market Report Structure
3. Lipid Disorder Treatment Market Trends And Strategies
4. Lipid Disorder Treatment Market – Macro Economic Scenario
5. Lipid Disorder Treatment Market Size And Growth
…..
27. Lipid Disorder Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
